On November 30, 2023 Immix Biopharma, Inc. (Nasdaq: IMMX) ("ImmixBio", "Company", "We" or "Us") a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, reported that it will present and host institutional investor meetings at the 2023 JMP Securities Hematology and Oncology Summit (Press release, Immix Biopharma, NOV 30, 2023, View Source [SID1234638067]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The JMP Securities Hematology and Oncology Summit

Presentation Date: Tuesday, December 5, 2023
Presentation Time: 3:30 pm ET
Location: Virtual
Webcast: Link
Investor Meetings: The IMMX Team will be available for institutional investor meetings during the conference.
The presentation will be broadcast live and archived on www.immixbio.com under "Events & Presentations" in the Investor Relations section. A replay of the webcast will be available on the Company’s website for approximately 90 days.